

## IRB Fees - Effective July 1, 2018

Institutional Review Board (IRB) fees are assessed for all industry sponsored research projects that meet the following NIH definition of a clinical trial: "A research study<sup>1</sup> in which one or more human subjects<sup>2</sup> are prospectively assigned<sup>3</sup> to one or more interventions<sup>4</sup> (which may include placebo or other control) to evaluate the effects of those interventions on health-related biomedical or behavioral outcomes<sup>5</sup>."

Research projects reviewed by the MCW IRB and supported by a biomedical industry sponsor (typically drug or medical device companies, but not limited to those industries) are subject to the IRB review fee. Fees are assessed for BOTH industry-sponsored and "investigator-initiated" for-profit funded projects.

When the MCW IRB defers IRB review responsibility for a research project supported by an industry sponsor to a different\* single or central IRB, the study is subject to the Administrative oversight fee. Only the MCW IRB reliance specialist has the authority to permit deferral of MCW IRB review responsibility to a different single or central IRB.

The table below lists the pricing, which will go into effect for all new industry sponsored studies submitted on or after July 1, 2018:

<b>Fee Name</b>	<b>Amount (7/1/18)</b>
<b>IRB Review</b>	\$7000
<b>Administrative Oversight<sup>a</sup></b>	\$3500
<sup>a</sup> Reliance processing and oversight fee for projects deferred to an external IRB.	

The MCW IRB will assess a one-time, all-inclusive initial review fee. This fee should be included in the budget